Manufactured by AngioDynamics, Inc., the Smart Port CT is a medical device designed for patients requiring repeat access to their vascular system for treatments like chemotherapy, intravenous fluids and medications. The device has become the subject of lawsuits due to its failure mechanisms, which has caused severe injuries and, in some cases, death.
The Bard PowerPort is manufactured by C.R. Bard, a wholly-owned subsidiary of Becton Dickinson and Co. Similar to the Smart Port CT, the Bard PowerPort is a medical device that is surgically implanted into the body to allow for repeated access to a vein. The device delivers medications, intraveneous fluids, nutrition or blood products directly into the bloodstream.
Numerous reports have highlighted two primary ways in which the Smart Port CT and the Bard PowerPort are failing:
Patients who have suffered from these device failures have sued the manufacturers of these port devices, AngioDynamics, Inc. and its subsidiary Navilyst Medical, as well as C.R. Bard. The complaints allege that the companies:
Medical research has shown that the polyurethane catheter in these devices, which contains a high concentration of barium sulfate for radiopacity (the ability to be seen on X-rays or scans), is prone to surface degradation and wear. This degradation increases the risk of infections and catheter fractures, leading to dangerous health complications for patients.
Injuries reported by patients affected by the Smart Port CT/Bard PowerPort failures include:
Many patients have needed additional surgeries to remove these devices and address the complications caused by their failures. This has resulted in significant emotional, physical and financial burdens on both patients and their families.
If you or a loved one has been harmed by a Smart Port CT or Bard PowerPort device, contact Pope McGlamry today for a free consultation. We work on a contingency fee basis, meaning you do not pay anything unless we win your case.
Call our Atlanta office or submit your free case evaluation online.